BridgeBio Pharma LLC and BridgeBio Pharma, Inc. Acquire 17.5% Stake in BridgeBio Oncology Therapeutics, Inc.

BridgeBio Pharma LLC and BridgeBio Pharma, Inc. have filed a Schedule 13D with the SEC, disclosing their acquisition of a 17.5% stake in BridgeBio Oncology Therapeutics, Inc. The acquisition was completed on August 11, 2025, following a business combination agreement. The Reporting Persons, BridgeBio Pharma LLC and BridgeBio Pharma, Inc., now hold 13,878,554 shares of common stock, including options to purchase additional shares. The shares were acquired for investment purposes, and the Reporting Persons may engage in discussions with the Issuer's board and management regarding business, operations, and strategic direction. The filing also includes details of a lock-up agreement and an amended and restated registration rights agreement, which restrict the transfer of shares for a specified period and grant certain registration rights to the Reporting Persons.